Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Guangxi Medical University Cancer Hospital, Nanning, Guangxi Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Henan Cancer Hospital, Zhengzhou, Henan